.png){kind=icon}
.png){kind=icon}
Return
Complement, interferon and lupus
.png){kind=icon}
PRE
AI
DOI：10.1016/j.coi.2012.08.004.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The complement pathway was implicated in the immunopathogenesis of lupus and other autoimmune disorders decades ago. The apparent paradox that early complement component (C1q, C2 and C4) deficiencies predispose to lupus has been explained by the beneficial roles of these proteins in promoting the clearance of immune complexes (ICs) and apoptotic cells. Recent findings demonstrate that, in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha, the cytokine with potent immune adjuvant properties. C1q opsonized apoptotic cells also exert an immunosuppressive effect through cytokine regulation and the stimulation of additional opsonins by macrophages. C1q was recently reported to impede neutrophil extracellular trap (NET) degradation. NETs are known to promote type I IFN production in SLE by providing a source of antigen for the formation of ICs as well as through direct pDC activation by cathelicidin (LL37). Together, these findings provide both direct and indirect links between two key pathways implicated in lupus pathogenesis: complement and IFN.
Keywords:
PLASMACYTOID DENDRITIC CELLS
MER TYROSINE KINASE
C1Q DEFICIENCY
DISEASE-ACTIVITY
APOPTOTIC CELLS
ANTI-C1Q ANTIBODIES
RENAL-DISEASE
RECEPTOR
CLEARANCE
PHAGOCYTOSIS
Journal
IF:
5.8
Papers:
3.4K
Citations:
9.5K